These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10756361)

  • 1. Amifostine in the treatment of low-risk myelodysplastic syndromes.
    Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
    Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
    Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
    Musch E; Malek M; Chrissafidou A
    Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Tsiara SN; Kapsali HD; Panteli K; Christou L; Bourantas KL
    J Exp Clin Cancer Res; 2001 Mar; 20(1):35-8. PubMed ID: 11370827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine.
    Ribeiro E; Lima CS; Metze K; Souza CA; Lorand-Metze I
    In Vivo; 2003; 17(2):181-4. PubMed ID: 12792983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
    Grossi A; Musto P; Santini V; Balestri F; Fabbri A; Falcone A; Sanpaolo G
    Haematologica; 2002 Mar; 87(3):322-3. PubMed ID: 11869946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myelodisplasic syndromes diagnosed in a geriatric hospital: morphological profile in 100 patients].
    Dewulf G; Gouin I; Pautas E; Gaussem P; Chaïbi P; Andreux JP; Siguret V
    Ann Biol Clin (Paris); 2004; 62(2):197-202. PubMed ID: 15047472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia.
    Bessho M; Jinnai I; Matsuda A; Saito M; Hirashima K
    Int J Cell Cloning; 1990 Nov; 8(6):445-58. PubMed ID: 2273298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome.
    Arboscello E; Botta M; Lerza R; Bogliolo G; Clavio M; Miglino M; Mencoboni M; Pannacciulli I
    Anticancer Res; 2002; 22(3):1819-24. PubMed ID: 12168875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.
    Schanz J; Jung H; Wörmann B; Gassmann W; Petersen T; Hinke A; Haase D
    Leuk Res; 2009 Sep; 33(9):1183-8. PubMed ID: 19411105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
    List AF; Brasfield F; Heaton R; Glinsmann-Gibson B; Crook L; Taetle R; Capizzi R
    Blood; 1997 Nov; 90(9):3364-9. PubMed ID: 9345018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.
    Platzbecker U; Haase M; Herbst R; Hänel A; Voigtmann K; Thiede CH; Mohr B; Schleyer E; Leopold T; Orth M; Hänel M; Ehninger G; Bornhäuser M
    Br J Haematol; 2005 Mar; 128(5):625-30. PubMed ID: 15725083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome.
    Metzgeroth G; Rosée PL; Kuhn C; Schultheis B; Dorn-Beineke A; Hehlmann R; Hastka J
    Eur J Haematol; 2007 Jul; 79(1):8-16. PubMed ID: 17532764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
    Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
    Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amifostine (Ethyol) as modulator of hepatic and biliary toxicity from intraarterial hepatic chemoembolization: results of a phase I study.
    Fiorentini G; Giovanis P; Leoni M; De Giorgi U; Cariello A; Dazzi C; Caldeo A
    Hepatogastroenterology; 2001; 48(38):313-6. PubMed ID: 11379297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
    Yilmaz A; Kaufmann CC; Binder C; Wörmann B; Haase D
    Ann Hematol; 2001 Jan; 80(1):53-7. PubMed ID: 11233778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.